Citadel Advisors
LYEL icon

Citadel Advisors’s Lyell Immunopharma LYEL Stock Holding History

Citadel Advisors’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,000
Closed -$492K – 13698
2025
Q4 		$492K Sell
16,000
-750
-4% -$16.8K ﹤0.01% 9059
2025
Q3 		$272K Buy
16,750
+760
+5% +$8.68K ﹤0.01% 10588
2025
Q2 		$141K Buy
15,990
+15,690
+5,230% +$143K ﹤0.01% 11008
2025
Q1 		$3.23K Sell
300
-465
-61% -$5.7K ﹤0.01% 13980
2024
Q4 		$9.79K Buy
765
+755
+7,550% +$15K ﹤0.01% 13627
2024
Q3 		$276 Sell
10
-365
-97% -$10.7K ﹤0.01% 14059
2024
Q2 		$10.9K Buy
375
+80
+27% +$3.81K ﹤0.01% 13064
2024
Q1 		$13.2K Buy
295
+225
+321% +$9.63K ﹤0.01% 13312
2023
Q4 		$2.72K Sell
70
-40
-36% -$1.44K ﹤0.01% 13666
2023
Q3 		$3.23K Sell
110
-60
-35% -$2.85K ﹤0.01% 13613
2023
Q2 		$10.8K Buy
170
+10
+6% +$553 ﹤0.01% 13175
2023
Q1 		$7.55K Buy
160
+60
+60% +$3.21K ﹤0.01% 13711
2022
Q4 		$6.94K Buy
+100
New +$9.93K ﹤0.01% 13869
2022
Q2 		– Sell
-610
Closed -$62K – 13602
2022
Q1 		$62K Sell
610
-150
-20% -$18.2K ﹤0.01% 12655
2021
Q4 		$118K Buy
+760
New +$169K ﹤0.01% 12544

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
GP
GSK plc London $599M AUM
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Citadel Advisors's LYEL Position: Q1 2026 in Review

Citadel Advisors increased its Lyell Immunopharma (LYEL) stake by 17% in Q1 2026, buying an estimated $1.33M and bringing the position to 381,462 shares worth $7.65M. The position accounts for ﹤0.01% of the portfolio, ranked #3653.

Citadel Advisors first reported a position in LYEL in Q2 2021 and has held it in 18 quarters since. The position peaked at $9.99M in Q4 2025. 74 funds tracked by Wall St. Rank hold LYEL as of Q1 2026.

  • Citadel Advisors held 381,462 shares of Lyell Immunopharma worth $7.65M as of Q1 2026.
  • Citadel Advisors bought 56,761 Lyell Immunopharma shares in Q1 2026, an estimated $1.33M.
  • Lyell Immunopharma made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3653 holding.
  • Citadel Advisors first reported a position in Lyell Immunopharma in Q2 2021 and has held it in 18 quarters since.
  • Citadel Advisors's Lyell Immunopharma position peaked at $9.99M in Q4 2025.
  • 74 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.